Bandera Partners LLC Has $1.37 Million Holdings in Dyadic International Inc. $DYAI

Bandera Partners LLC decreased its position in shares of Dyadic International Inc. (NASDAQ:DYAI) by 11.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,383,308 shares of the biotechnology company’s stock after selling 183,600 shares during the quarter. Dyadic International accounts for approximately 0.6% of Bandera Partners LLC’s investment portfolio, making the stock its 14th largest position. Bandera Partners LLC owned 4.60% of Dyadic International worth $1,369,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Chapin Davis Inc. raised its position in shares of Dyadic International by 4.7% in the 2nd quarter. Chapin Davis Inc. now owns 882,849 shares of the biotechnology company’s stock valued at $874,000 after buying an additional 40,000 shares in the last quarter. AlphaCore Capital LLC acquired a new stake in shares of Dyadic International during the 2nd quarter worth approximately $50,000. Finally, Bank of America Corp DE increased its stake in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares during the last quarter. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DYAI has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyadic International in a report on Tuesday, November 11th. Craig Hallum began coverage on Dyadic International in a research note on Monday, September 8th. They issued a “buy” rating on the stock. Finally, HC Wainwright assumed coverage on Dyadic International in a research note on Thursday, October 23rd. They set a “buy” rating and a $3.00 target price for the company. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $3.00.

Dyadic International Stock Performance

Shares of DYAI stock opened at $0.91 on Tuesday. The stock has a market capitalization of $32.93 million, a PE ratio of -4.79 and a beta of 1.00. The business’s 50 day simple moving average is $1.06 and its 200 day simple moving average is $1.00. The company has a debt-to-equity ratio of 5.40, a current ratio of 2.02 and a quick ratio of 2.02. Dyadic International Inc. has a one year low of $0.71 and a one year high of $2.20.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Dyadic International had a negative return on equity of 355.39% and a negative net margin of 134.84%.The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.22 million. As a group, research analysts forecast that Dyadic International Inc. will post -0.18 earnings per share for the current year.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.